This quarterly report on Form 10-Q, including the following management’s discussion and analysis, contains forward-looking information that you should read in conjunction with the condensed consolidated financial statements and notes to the condensed consolidated financial statements that we have included elsewhere in this report. For this purpose, any statements contained in this report that are not statements of historical fact may be deemed to be forward-looking statements. Words such as “believes,” “plans,” “anticipates,” “intends,” “expects,” “will” and similar expressions are intended to identify forward-looking statements. Our actual results may differ materially from the plans, intentions or expectations we disclose in the forward-looking statements we make. We have included important factors below under the heading “Risk Factors” in Part II, Item 1A. that we believe could cause actual results to differ materially from the forward-looking statements we make. We are not obligated to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise. Overview Our fiscal year ends on the Sunday nearest December 31. We report fiscal years under a 52/53 week format and as a result, certain fiscal years will contain 53 weeks. The fiscal year ending January 3, 2027 (“fiscal year 2026”) will include 53 weeks, and the fiscal year ended December 28, 2025 (“fiscal year 2025”) included 52 weeks. We are a leading provider of health science solutions, technologies, expertise and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what’s possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more. The principal products and services of our two reportable segments are: •Life Sciences. Provides products and services targeted towards life sciences customers. •Diagnostics. Develops diagnostics, tools and applications focused on clinically-oriented customers, especially within the areas of reproductive health, immunodiagnostics and emerging market diagnostics. Overview of the Second Quarter of Fiscal Year 2026 Our overall revenue in the second quarter of fiscal year 2026 was $729.7 million which increased by $9.4 million, or 1%, as compared to the second quarter of fiscal year 2025, reflecting an increase of $16.6 million, or 5%, in our Diagnostics segment revenue, and a decrease of $7.2 million, or 2%, in our Life Sciences segment revenue. The increase in our Diagnostics segment revenue for the second quarter of fiscal year 2026 was driven by both our Reproductive Health business and favorable changes in foreign exchange rates. The decrease in our Life Sciences segment revenue for the second quarter of fiscal year 2026 was driven by a decline in revenue in our Software business. Our consolidated gross margins increased 260 basis points from 54.5% to 57.1% in the second quarter of fiscal year 2026, as compared to the second quarter of fiscal year 2025, primarily due to tariff refunds and product mix shift. Our consolidated operating margins decreased from 12.6% to 12.2% in the second quarter of fiscal year 2026, as compared to the second quarter of fiscal year 2025, primarily due to restructuring charges and digital investments. Critical Accounting Policies and Estimates The preparation of condensed consolidated financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosure of contingent assets and liabilities. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. Critical accounting policies are those policies that affect our more significant judgments and estimates used in the preparation of our condensed consolidated financial statements. We believe our critical accounting policies include policies regarding valuation of goodwill and income taxes. 25 Table of Contents For a more detailed discussion of our critical accounting policies and estimates, refer to the Notes to our audited consolidated financial statements and Item 7. “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” in our Annual Report on Form 10-K for the fiscal year ended December 28, 2025 (our “2025 Form 10-K”), as filed with the Securities and Exchange Commission. There have been no significant changes in our critical accounting policies and estimates during the six months ended July 5, 2026. Consolidated Results of Continuing Operations Revenue Revenue for the three months ended July 5, 2026 was $729.7 million, as compared to $720.3 million for the three months ended June 29, 2025, an increase of $9.4 million, or 1%. The analysis in the remainder of this paragraph compares segment revenue and includes the effect of foreign exchange rate fluctuations. Life Sciences segment revenue was $358.7 million for the three months ended July 5, 2026, as compared to $365.9 million for the three months ended June 29, 2025, a decrease of $7.2 million, or 2%, driven by a decrease of $10.2 million in Software revenue, partially offset by an increase of $3.0 million in Life Sciences Solutions revenue. Diagnostics segment revenue was $371.0 million for the three months ended July 5, 2026, as compared to $354.4 million for the three months ended June 29, 2025, an increase of $16.6 million, or 5%, due to an increase of $20.7 million in Reproductive Health revenue, partially offset by a decrease of $4.1 million in Immunodiagnostics revenue. Revenue for the six months ended July 5, 2026 was $1,440.8 million, as compared to $1,385.0 million for the six months ended June 29, 2025, an increase of $55.8 million, or 4%. The analysis in the remainder of this paragraph compares segment revenue and includes the effect of foreign exchange rate fluctuations. Life Sciences segment revenue was $720.5 million for the six months ended July 5, 2026, as compared to $706.3 million for the six months ended June 29, 2025, an increase of $14.3 million, or 2%, driven by an increase of $16.5 million in Life Sciences Solutions revenue, partially offset by a decrease of $2.3 million in Software revenue. Diagnostics segment revenue was $720.3 million for the six months ended July 5, 2026, as compared to $678.8 million for the six months ended June 29, 2025, an increase of $41.5 million, or 6%, due to an increase of $41.3 million in Reproductive Health revenue and an increase of $0.2 million in Immunodiagnostics revenue. Both the Life Sciences and the Diagnostics segments benefited from an extra fiscal week for the six months ended July 5, 2026. Cost of Revenue Cost of revenue for the three months ended July 5, 2026 was $312.8 million, as compared to $327.7 million for the three months ended June 29, 2025, a decrease of $14.9 million, or 5%. As a percentage of revenue, cost of revenue decreased to 42.9% for the three months ended July 5, 2026, from 45.5% for the three months ended June 29, 2025, resulting in an increase in gross margin of 260 basis points to 57.1% for the three months ended July 5, 2026, from 54.5% for the three months ended June 29, 2025, primarily due to tariff refunds and product mix shift. Amortization of intangible assets was $34.8 million for the three months ended July 5, 2026, as compared to $36.5 million for the three months ended June 29, 2025. Cost of revenue for the six months ended July 5, 2026 was $636.3 million, as compared to $616.9 million for the six months ended June 29, 2025, an increase of $19.3 million, or 3%. As a percentage of revenue, cost of revenue decreased to 44.2% for the six months ended July 5, 2026, from 44.5% for the six months ended June 29, 2025, resulting in an increase in gross margin of 40 basis points to 55.8% for the six months ended July 5, 2026, from 55.5% for the six months ended June 29, 2025, primarily due to tariff refunds and product mix shift. Amortization of intangible assets was $69.8 million for the six months ended July 5, 2026, as compared to $70.9 million for the six months ended June 29, 2025. On February 20, 2026, the United States Supreme Court ruled that the International Emergency Economic Powers Act does not authorize the imposition of tariffs. In April 2026, the U.S. Customs and Border Protection (CBP) announced a new administrative process for importers to utilize in seeking to obtain refunds. Through the established CBP refund process, the Company applied for $20.2 million of refunds and received $16.2 million through July 5, 2026. The timing and amount of additional recoveries remain uncertain and will depend on the scope and timing of court or administrative developments and completion of applicable administrative steps. Accordingly, refunds have been recorded in income upon receipt of payment, and no refund receivable has been recorded as of July 5, 2026. As a result, $16.2 million of refunds were recorded in cost of revenue for the three months ended July 5, 2026. 26 Table of Contents Selling, General and Administrative Expenses Selling, general and administrative expenses for the three months ended July 5, 2026 were $278.6 million, as compared to $248.5 million for the three months ended June 29, 2025, an increase of $30.1 million, or 12%. As a percentage of revenue, selling, general and administrative expenses increased and were 38.2% for the three months ended July 5, 2026, as compared to 34.5% for the three months ended June 29, 2025. Amortization of intangible assets increased and was $50.1 million for the three months ended July 5, 2026, as compared to $48.8 million for the three months ended June 29, 2025. Restructuring and other costs increased and were $35.5 million for the three months ended July 5, 2026, as compared to $11.2 million for the three months ended June 29, 2025. Restructuring and other costs in the second quarter of fiscal year 2026 primarily consisted of charges associated with workforce reductions and facility consolidations in an effort to streamline operations, other exit costs, abandonments or associated asset write-downs, costs of terminating certain lease agreements or contracts, as well as costs associated with relocating facilities. In the second quarter of fiscal year 2026, severance actions associated with facility consolidations and cost reduction measures affected approximately 3% of our workforce. The above increases were partially offset by a decrease in purchase accounting adjustments, which were $1.7 million for the three months ended July 5, 2026, and primarily consisted of a change in contingent consideration, as compared to $2.0 million for the three months ended June 29, 2025. Acquisition and divestiture-related expenses, which primarily consisted of legal and integration costs, were $0.1 million for the three months ended July 5, 2026, as compared to $1.2 million for the three months ended June 29, 2025. Significant litigation matters and settlements decreased, and were $0.1 million for the three months ended July 5, 2026, as compared to $1.1 million for the three months ended June 29, 2025. Transformation costs were a net credit of $0.7 million for the three months ended July 5, 2026. Excluding the items noted above, selling, general and administrative expenses increased due to digital investments and employee incentive compensation. Selling, general and administrative expenses for the six months ended July 5, 2026 were $532.5 million, as compared to $498.2 million for the six months ended June 29, 2025, an increase of $34.2 million, or 7%. As a percentage of revenue, selling, general and administrative expenses increased and were 37.0% for the six months ended July 5, 2026, as compared to 36.0% for the six months ended June 29, 2025. Amortization of intangible assets increased and was $100.2 million for the six months ended July 5, 2026, as compared to $97.1 million for the six months ended June 29, 2025. Restructuring and other costs increased and were $46.2 million for the six months ended July 5, 2026, as compared to $14.4 million for the six months ended June 29, 2025. Restructuring and other costs in the first and second quarters of fiscal year 2026 primarily consisted of charges associated with workforce reductions and facility consolidations in an effort to streamline operations, other exit costs, abandonments or associated asset write-downs, costs of terminating certain lease agreements or contracts, as well as costs associated with relocating facilities. For the six months ended July 5, 2026, severance actions associated with facility consolidations and cost reduction measures affected approximately 5% of our workforce. Costs for significant environmental matters were a net credit of $1.2 million for the six months ended June 29, 2025. The above increases were also partially offset by a decrease in significant litigation matters and settlements, which was $0.1 million for the six months ended July 5, 2026, as compared to $11.7 million for the six months ended June 29, 2025. Disposition of businesses and assets, net were a net credit of $5.1 million for the six months ended July 5, 2026. Acquisition and divestiture-related expenses, which primarily consisted of legal and integration costs, decreased and were $0.4 million for the six months ended July 5, 2026, as compared to $3.8 million for the six months ended June 29, 2025. Transformation costs were $0.1 million for the six months ended July 5, 2026. Purchase accounting adjustments, which primarily consisted of a change in contingent consideration, remained flat at $1.6 million for both the six months ended July 5, 2026 and the six months ended June 29, 2025. Excluding the items noted above, selling, general and administrative expenses increased due to the extra fiscal week in the first quarter as compared to the same period in the prior year, digital investments, and employee incentive compensation. Research and Development Expenses Research and development expenses for the three months ended July 5, 2026 were $49.0 million, as compared to $53.3 million for the three months ended June 29, 2025, a decrease of $4.3 million, or 8%. As a percentage of revenue, research and development expenses decreased and were 6.7% for the three months ended July 5, 2026, as compared to 7.4% for the three months ended June 29, 2025. The decrease in research and development expenses was primarily driven by cost containment initiatives. Research and development expenses for both the six months ended July 5, 2026 and the six months ended June 29, 2025 were flat at $106.9 million. As a percentage of revenue, research and development expenses decreased and were 7.4% for the six months ended July 5, 2026, as compared to 7.7% for the six months ended June 29, 2025. The change in research and development expenses was primarily driven by cost containment initiatives offsetting increased costs due to the extra fiscal week in the six months ended July 5, 2026 . Interest and Other Expense, Net Interest and other expense, net, consisted of the following: 27 Table of Contents Three Months Ended Six Months Ended July 5, 2026 June 29, 2025 July 5, 2026 June 29, 2025 (In thousands) Interest income $ (5,259) $ (8,345) $ (11,563) $ (18,426) Interest expense 22,990 22,937 47,708 45,901 Change in fair value of investments 5,251 1,955 9,455 (1,118) Other components of net periodic pension cost 1,462 1,695 1,211 8,482 Foreign exchange losses and other expense, net 1,341 3,868 4,868 7,119 Total interest and other expense, net $ 25,785 $ 22,110 $ 51,679 $ 41,958 The decrease in interest income for the three months ended July 5, 2026 as compared to the three months ended June 29, 2025 was primarily due to decreases in interest rates and lower cash balances. Interest expense for the three months ended July 5, 2026 remained flat as compared to the same period in the prior year. The decrease in interest income for the six months ended July 5, 2026 as compared to the six months ended June 29, 2025 was primarily due to decreases in interest rates and lower cash balances. Interest expense was higher for the six months ended July 5, 2026 as compared to the same period in the prior year primarily due to the extra fiscal week in the first quarter as compared to the same period in the prior year, which resulted in one additional week of accrued interest as compared to the six months ended June 29, 2025. Provision for Income Taxes The provision for income taxes from continuing operations was $10.1 million for the three months ended July 5, 2026, as compared to $13.4 million for the three months ended June 29, 2025. The provision for income taxes from continuing operations was $19.1 million for the six months ended July 5, 2026, as compared to $24.1 million for the six months ended June 29, 2025. The effective tax rate from continuing operations was 15.8% and 16.9% for the three and six months ended July 5, 2026, as compared to 19.6% and 19.9% for the three and six months ended June 29, 2025. The effective tax rate for the three and six months ended July 5, 2026 was lower as compared to the three and six months ended June 29, 2025 primarily due to favorable impacts related to state deferred tax remeasurements in fiscal year 2026 of $2.4 million. We expect that the effective tax rate on continuing operations, before discrete items, will be approximately 20% during fiscal year 2026. Reporting Segment Results of Continuing Operations Life Sciences Revenue for the three months ended July 5, 2026 was $358.7 million, as compared to $365.9 million for the three months ended June 29, 2025, a decrease of $7.2 million, or 2%. The decrease in our Life Sciences segment revenue during the three months ended July 5, 2026 was driven by a decrease of $10.2 million in Software revenue, partially offset by an increase of $3.0 million in Life Sciences Solutions revenue. Revenue for the six months ended July 5, 2026 was $720.5 million, as compared to $706.3 million for the six months ended June 29, 2025, an increase of $14.3 million, or 2%. The increase in our Life Sciences segment revenue during the six months ended July 5, 2026 was driven by an increase of $16.5 million in Life Sciences Solutions revenue, partially offset by a decrease of $2.3 million in Software revenue. Our Life Sciences segment benefited from an extra fiscal week for the six months ended July 5, 2026. Segment operating income for the three months ended July 5, 2026 was $111.5 million, as compared to $115.5 million for the three months ended June 29, 2025, a decrease of $3.9 million, or 3%. Segment operating margin decreased 50 basis points in the three months ended July 5, 2026, as compared to the three months ended June 29, 2025, primarily due to strategic investments in software and new product development, partially offset by favorable product mix shift. Segment operating income for the six months ended July 5, 2026 was $215.5 million, as compared to $221.2 million for the six months ended June 29, 2025, a decrease of $5.7 million, or 3%. Segment operating margin decreased 150 basis points in the six months ended July 5, 2026, as compared to the six months ended June 29, 2025, primarily due to strategic investments in software and new product development and impact of the extra fiscal week in the six months ended July 5, 2026. 28 Table of Contents Diagnostics Revenue for the three months ended July 5, 2026 was $371.0 million, as compared to $354.4 million for the three months ended June 29, 2025, an increase of $16.6 million, or 5%. The increase in our Diagnostics segment revenue during the three months ended July 5, 2026 was driven by an increase of $20.7 million in Reproductive Health revenue, partially offset by a decrease of $4.1 million in Immunodiagnostics revenue. Revenue for the six months ended July 5, 2026 was $720.3 million, as compared to $678.8 million for the six months ended June 29, 2025, an increase of $41.5 million, or 6%. The increase in our Diagnostics segment revenue during the six months ended July 5, 2026 was driven by an increase of $41.3 million in Reproductive Health revenue and an increase of $0.2 million in Immunodiagnostics revenue. Our Diagnostics segment benefited from an extra fiscal week in the six months ended July 5, 2026. Segment operating income for the three months ended July 5, 2026 was $112.9 million, as compared to $89.4 million for the three months ended June 29, 2025, an increase of $23.4 million, or 26%. Segment operating margin increased 520 basis points in the three months ended July 5, 2026, as compared to the three months ended June 29, 2025, primarily due to tariff refunds and cost containment initiatives. Segment operating income for the six months ended July 5, 2026 was $189.0 million, as compared to $163.4 million for the six months ended June 29, 2025, an increase of $25.6 million, or 16%. Segment operating margin increased 220 basis points in the six months ended July 5, 2026, as compared to the six months ended June 29, 2025, primarily due to tariff refunds and cost containment initiatives, partially offset by product mix shift and the impact of the extra fiscal week in the six months ended July 5, 2026. Liquidity and Capital Resources We require cash to pay our operating expenses, make capital expenditures, make strategic acquisitions, service our debt and other long-term liabilities, repurchase shares of our common stock and pay dividends on our common stock. Our principal sources of funds are our internal operations, borrowing capacity available under our senior unsecured revolving credit facility and access to debt markets. We anticipate that our internal operations will generate sufficient cash to fund our operating expenses, capital expenditures, acquisitions, interest payments on our debt and dividends on our common stock, for the foreseeable future, including at least the next 12 months. At July 5, 2026, we had cash and cash equivalents of $1,022.9 million, of which $544.5 million was held by our non-U.S. subsidiaries, and we had $1.5 billion of borrowing capacity available under our senior unsecured revolving credit facility. We use a variety of cash redeployment and financing strategies to ensure that our worldwide cash is available in the locations in which it is needed. On October 23, 2025, our Board of Directors (our “Board”) authorized us to repurchase shares of common stock for an aggregate amount up to $1.0 billion under a stock repurchase program (the “Repurchase Program”). The Repurchase Program will expire on October 22, 2027 unless terminated earlier by our Board and may be suspended or discontinued at any time. During the three months ended July 5, 2026, we repurchased 93,303 shares of common stock under the Repurchase Program for an aggregate cost of $7.8 million. As of July 5, 2026, $792.7 million remained available for aggregate repurchases of shares under the Repurchase Program. There have been no share repurchases subsequent to the second quarter of fiscal year 2026. If we continue to repurchase shares, the Repurchase Program will be funded using our existing financial resources, including cash and cash equivalents, and our existing senior unsecured revolving credit facility. As of July 5, 2026, we may have to pay contingent consideration related to acquisitions with open contingency periods of up to $71.2 million. As of July 5, 2026, we have recorded contingent consideration obligations of $15.4 million, of which $4.0 million was recorded in accrued expenses and other current liabilities, and $11.4 million was recorded in long-term liabilities. The maximum earnout period for acquisitions with open contingency periods is 5.4 years from July 5, 2026, and the remaining weighted average expected earnout period at July 5, 2026 was 3.0 years. Distressed global financial markets could adversely impact general economic conditions by reducing liquidity and credit availability, creating increased volatility in security prices, widening credit spreads, increasing the cost of borrowings and decreasing valuations of certain investments. The widening of credit spreads may create a less favorable environment for certain of our businesses and may affect the fair value of financial instruments that we issue or hold. Increases in credit spreads, as well as limitations on the availability of credit at rates we consider to be reasonable, could affect our ability to borrow under future potential facilities on a secured or unsecured basis, which may adversely affect our liquidity and results of operations. In 29 Table of Contents difficult global financial markets, we may be forced to fund our operations at a higher cost, or we may be unable to raise as much funding as we need to support our business activities or fund our strategic transactions. We and our subsidiaries may from time to time, in our sole discretion, purchase, repay, redeem or retire any of our outstanding debt securities (including any publicly issued debt securities), in privately negotiated or open market transactions, by tender offer or otherwise, or extend or refinance any of our outstanding indebtedness. Principal factors that could affect the availability of our internally generated funds include: •changes in sales due to weakness in markets in which we sell our products and services, and •changes in our working capital requirements and capital expenditures. Principal factors that could affect our ability to obtain cash from external sources include: •financial covenants contained in the financial instruments controlling our borrowings that limit our total borrowing capacity, •increases in interest rates applicable to our outstanding variable rate debt, •a ratings downgrade that could limit the amount we can borrow under our senior unsecured revolving credit facility and our overall access to the corporate debt market, •increases in interest rates or credit spreads, as well as limitations on the availability of credit, that affect our ability to borrow under future potential facilities on a secured or unsecured basis, •a decrease in the market price for our common stock, and •volatility in the public debt and equity markets. Cash Flows Operating Activities. Net cash provided by operating activities of our continuing operations was $317.8 million for the six months ended July 5, 2026, as compared to $268.4 million for the six months ended June 29, 2025, an increase of $49.4 million. The cash provided by operating activities for the six months ended July 5, 2026 was principally a result of adjustments for non-cash charges aggregating to $281.3 million, including depreciation and amortization of $207.1 million and income from continuing operations of $94.4 million, partially offset by a net cash decrease in working capital of $57.8 million, primarily due to annual employee incentive compensation payout and timing of inventory build and vendor payments, partially offset by robust collections performance. The cash provided by operating activities for the six months ended June 29, 2025 was principally a result of adjustments for non-cash charges aggregating to $233.7 million, including depreciation and amortization of $200.2 million, and income from continuing operations of $96.9 million, partially offset by a net cash decrease in working capital of $62.2 million. Investing Activities. Net cash used in investing activities of our continuing operations was $81.8 million for the six months ended July 5, 2026, as compared to $34.6 million for the six months ended June 29, 2025, an increase of $47.2 million primarily due to cash paid for acquisitions, net of cash acquired of $67.1 million during the six months ended July 5, 2026. During the six months ended July 5, 2026, net cash used for capital expenditures was $30.8 million, as compared to $34.9 million for the six months ended June 29, 2025. During the six months ended July 5, 2026, purchases of investments and notes receivables were $3.6 million. The cash used in investing activities during the six months ended July 5, 2026 was partially offset by $12.0 million of proceeds from disposition of property, plant and equipment. During the six months ended July 5, 2026, proceeds from investments and notes receivable amounted to $7.5 million. During the six months ended July 5, 2026, proceeds from disposition of businesses and assets amounted to $0.2 million, remaining flat compared to the six months ended June 29, 2025. Financing Activities. Net cash used in financing activities was $112.1 million for the six months ended July 5, 2026, as compared to $466.1 million for the six months ended June 29, 2025, a decrease of $354.1 million. During the six months ended July 5, 2026, we repurchased shares of our common stock for a total cost of $102.5 million, as compared to $447.5 million in the prior year period. We paid $15.7 million in dividends for the six months ended July 5, 2026, as compared to $16.7 million for the six months ended June 29, 2025. We paid $0.4 million for acquisition-related contingent consideration during the six months ended July 5, 2026, as compared to $2.0 million for the six months ended June 29, 2025. During the six months ended June 29, 2025, we made net payments of $2.6 million on debts. The cash used in financing activities during the six months ended July 5, 2026 was partially offset by proceeds from the issuance of common stock under our stock plans of $6.4 million during the six months ended July 5, 2026, as compared to $2.6 million for the six months ended June 29, 2025. 30 Table of Contents Borrowing Arrangements Subsequent to the second quarter of fiscal year 2026, we repaid upon maturity all of our outstanding €500,000 Principal 1.875% Senior Unsecured Notes due in 2026 (the “2026 Notes”) at an aggregate principal amount of €500.0 million ($571.2 million). See Note 7, Debt, in the Notes to Condensed Consolidated Financial Statements and Note 13, Debt, to our audited consolidated financial statements in the 2025 Form 10-K for a detailed discussion of our borrowing arrangements. Dividends Our Board declared a regular quarterly cash dividend of $0.07 per share for each of the first two quarters of fiscal year 2026 and in each quarter of fiscal year 2025. At July 5, 2026, we had accrued $7.8 million for dividends declared on April 30, 2026 for the second quarter of fiscal year 2026 that were paid in August 2026. On July 31, 2026, we announced that our Board had declared a quarterly dividend of $0.07 per share for the third quarter of fiscal year 2026 that will be payable in November 2026. In the future, our Board may determine to reduce or eliminate our common stock dividend in order to fund investments for growth, repurchase shares or conserve capital resources. Effects of Recently Adopted and Issued Accounting Pronouncements See Note 1, Nature of Operations and Accounting Policies, to our audited consolidated financial statements in the 2025 Form 10-K for a summary of recently adopted new accounting pronouncements during the fiscal year ended December 28, 2025. We have not adopted any new accounting pronouncements during the six months ended July 5, 2026.